Index- P/E- EPS (ttm)-4.58 Insider Own1.07% Shs Outstand78.52M Perf Week2.82%
Market Cap949.35M Forward P/E- EPS next Y-1.67 Insider Trans0.00% Shs Float37.92M Perf Month36.93%
Income-348.10M PEG- EPS next Q- Inst Own58.10% Short Float8.04% Perf Quarter-36.63%
Sales13.10M P/S72.47 EPS this Y-545.60% Inst Trans-0.75% Short Ratio2.42 Perf Half Y-75.11%
Book/sh8.67 P/B1.35 EPS next Y- ROA-41.70% Target Price76.67 Perf Year-84.32%
Cash/sh7.86 P/C1.49 EPS next 5Y26.00% ROE-48.10% 52W Range8.05 - 81.47 Perf YTD-75.35%
Dividend- P/FCF- EPS past 5Y- ROI-45.40% 52W High-85.66% Beta-
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin47.30% 52W Low45.09% ATR1.00
Employees378 Current Ratio7.70 Sales Q/Q-97.70% Oper. Margin- RSI (14)53.54 Volatility8.62% 9.06%
OptionableYes Debt/Eq0.00 EPS Q/Q-45.30% Profit Margin- Rel Volume0.36 Prev Close12.34
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.26M Price11.68
Recom1.60 SMA209.34% SMA504.74% SMA200-66.23% Volume453,771 Change-5.35%
Dec-09-21Initiated Siebert Williams Shank Buy $96
Jun-02-21Initiated Daiwa Securities Buy
Mar-15-21Initiated Needham Buy $75
Mar-03-21Reiterated H.C. Wainwright Buy $55 → $75
Feb-25-21Initiated Piper Sandler Overweight $75
Dec-07-20Initiated H.C. Wainwright Buy $55
Jul-27-20Initiated Cantor Fitzgerald Overweight $50
Feb-12-20Initiated China Renaissance Buy
Feb-11-20Initiated Jefferies Buy $16
Jul-06-22 08:00AM  
Jun-23-22 08:00AM  
Jun-15-22 08:30AM  
May-31-22 08:00AM  
May-26-22 05:01PM  
May-19-22 08:00AM  
May-12-22 06:16AM  
May-05-22 08:00AM  
Apr-28-22 04:01PM  
Apr-20-22 08:25PM  
Mar-31-22 08:00AM  
Mar-29-22 06:10AM  
Mar-25-22 08:00PM  
Mar-18-22 08:00AM  
Mar-15-22 02:22PM  
Mar-09-22 08:00AM  
Mar-03-22 08:00AM  
Mar-01-22 09:28AM  
Feb-26-22 12:58PM  
Feb-08-22 09:38AM  
Jan-28-22 08:00AM  
Jan-27-22 01:38PM  
Jan-18-22 08:00AM  
Jan-14-22 08:00AM  
Jan-12-22 08:00AM  
Jan-06-22 08:00AM  
Jan-04-22 09:32AM  
Dec-27-21 08:00AM  
Dec-20-21 08:00AM  
Dec-15-21 08:00AM  
Dec-14-21 06:00AM  
Dec-09-21 08:00AM  
Dec-08-21 08:00AM  
Dec-07-21 10:26AM  
Dec-03-21 08:00AM  
Nov-15-21 11:00AM  
Nov-13-21 08:41AM  
Nov-10-21 08:19AM  
Nov-09-21 08:05AM  
Nov-08-21 08:30AM  
Nov-04-21 09:00AM  
Nov-03-21 08:00AM  
Nov-01-21 08:00AM  
Oct-26-21 08:00AM  
Oct-22-21 08:00AM  
Oct-18-21 08:00AM  
Oct-13-21 08:00AM  
Oct-05-21 08:00AM  
Oct-01-21 08:00AM  
Sep-30-21 08:00AM  
Sep-28-21 08:27AM  
Sep-20-21 12:13PM  
Sep-13-21 08:03AM  
Sep-02-21 08:00AM  
Sep-01-21 12:53PM  
Aug-31-21 04:30PM  
Aug-30-21 08:00AM  
Aug-27-21 11:51AM  
Aug-19-21 07:00AM  
Aug-17-21 08:00AM  
Aug-11-21 08:00AM  
Jul-30-21 08:00AM  
Jul-29-21 08:00AM  
Jul-28-21 07:15AM  
Jul-27-21 08:35AM  
Jul-21-21 04:53AM  
Jul-09-21 08:00AM  
Jul-01-21 12:59PM  
Jun-30-21 08:00AM  
Jun-29-21 08:00AM  
Jun-25-21 08:00AM  
Jun-21-21 08:00AM  
Jun-14-21 01:41PM  
Jun-08-21 04:36AM  
Jun-02-21 08:00AM  
Jun-01-21 08:00AM  
May-27-21 08:00AM  
May-20-21 06:17AM  
May-19-21 06:00PM  
May-18-21 08:00AM  
May-14-21 07:00AM  
May-13-21 08:00AM  
Apr-29-21 08:00AM  
Apr-28-21 08:00AM  
Apr-26-21 09:58AM  
Apr-14-21 08:30AM  
Apr-06-21 08:00AM  
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.